Sugi Predict

Sugi Predict / Compounds / SCHEMBL1236491

SCHEMBL1236491

SCHEMBL1236491

COc1ccc(C=O)c(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.66
▸ TRIM24 O15164 1/20 0.63
▸ TYR P14679 1/20 0.63
▸ TRIM33 Q9UPN9 1/20 0.63
▸ ERN1 O75460 4/20 0.58
▸ TDP1 Q9NUW8 1/20 0.57
▸ CYP1A2 P05177 5/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ CYP1A1 P04798 3/20 0.48
▸ CYP1B1 Q16678 3/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ LMNA P02545 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8907495 0.89 ALDH1A1 (0.64) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL25333119 0.88 ALDH1A1 (0.53) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL2199528 0.86 ERN1 (0.61) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL2081406 0.83 CYP1A2 (0.50) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL2081404 0.83 CYP1A2 (0.50) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL3319231 0.83 CYP1A2 (0.48) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL12672585 0.83 ALDH1A1 (0.70) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL29957021 0.83 ALDH1A1 (0.70) ALDH1A1TRIM24TYRTRIM33ERN1
SCHEMBL18144233 0.82 AHR (0.57) ALDH1A1CYP1A2KDM4ECYP1A1CYP1B1
SCHEMBL31471572 0.82 TDP1 (0.47) ALDH1A1TRIM24TYRTRIM33ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110606855-B Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof 湘潭大学 2022-03-18 — — CN claimed
CN-110606855-A Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof 湘潭大学 2019-12-24 — — CN claimed
CN-1589136-A Pharmaceutical and cosmetic compositions containing aromatic aldehydes bearing oxygen-containing groups CUTANIX CORP (US) 2005-03-02 — — CN claimed
WO-2004080979-A1 NOVEL 3-(2-AMINO-4-PYRIMIDINYL)-4-HYDROXYPHENYL KETONE DERIVATIVES LG LIFE SCIENCES LTD. (KR) 2004-09-23 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-RE50527-E1 Covalent inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-08-12 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
CN-116234550-B Aromatic formyl substituted tricyclic compound and preparation method and application thereof 劲方医药科技(上海)股份有限公司 2024-12-27 — — CN disclosed
US-12173018-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2024-12-24 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
EP-0193055-B1 ANTITUMORALS(1,2-DIPHENYL-ETHYLENE DIAMINE)-PLATINUM (II) COMPLEXES ASTA Pharma AG (DE) 1990-05-16 — — EP disclosed
CN-87106895-A Phenoxyacetic acid derivatives and process for producing the same — 1988-04-20 — — CN disclosed
US-4730068-A SPECIAL EFFECT ON BREAST CANCER ASTA-WERKE AKTIENGESELLSCHAFT (DE) 1988-03-08 — — US disclosed
CN-86100815-A The preparation method who suppresses (1, the 2-diphenyl ethylene diamine)-platinum (II) complex compound of tumour — 1986-11-26 — — CN disclosed
EP-0193055-A1 Antitumorals(1,2-diphenyl-ethylene diamine)-platinum (II) complexes ASTA Pharma AG (DE) 1986-09-03 — — EP disclosed
EP-0111345-A2 Isoxazoles, useful as antiviral agents, and preparation thereof STERLING DRUG INC. (US) 1984-06-20 — — EP disclosed
US-4451476-A Isoxazoles as antiviral agents STERLING DRUG INC. (US) 1984-05-29 — — US disclosed
US-4360466-A N'-[2,6-Dichloro-4-(substituted-benzylideneamino)phenyl]-N,N-dimethylformamidines AMERICAN CYANAMID COMPANY (US) 1982-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB ALDH1A1 3824/4885TRIM24 2480/4885TYR 1810/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB ALDH1A1 3824/4885TRIM24 2480/4885TYR 1810/4885
US-12173018-B2 Penicillin-binding protein inhibitors PEPD, BPGM, EBPL ALDH1A1 2794/4885TRIM24 1981/4885TYR 2212/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB ALDH1A1 3824/4885TRIM24 2480/4885TYR 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.